Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570707 | 0.88 | BACE1 (0.48) | BACE1CTSD | |
| SCHEMBL570903 | 0.88 | BACE1 (0.50) | BACE1CTSD | |
| SCHEMBL10285421 | 0.77 | BACE1 (0.52) | BACE1CTSD | |
| SCHEMBL2372086 | 0.76 | BACE1 (0.54) | BACE1CTSD | |
| SCHEMBL10285494 | 0.75 | BACE1 (0.52) | BACE1CTSD | |
| SCHEMBL571111 | 0.75 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL570726 | 0.74 | BACE1 (0.50) | BACE1CTSD | |
| SCHEMBL2370782 | 0.74 | BACE1 (0.54) | BACE1CTSD | |
| SCHEMBL15468124 | 0.74 | BACE1 (0.52) | BACE1CTSD | |
| SCHEMBL2371441 | 0.74 | BACE1 (0.52) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2601197-B1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2601197-B1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130172343-A1 | Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors | AMGEN INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172343-A1 | Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors | AMGEN INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172343-A1 | Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors | AMGEN INC. (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2601197-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172343-A1 | Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.